p-Cresyl Sulfate

Uremic Toxins

Volumn , Issue , 2012, Pages 77-86

  Pletinck, Anneleen ^a   Vanholder, Raymond ^a   Glorieux, Griet ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Biological impact, p cresyl sulfate p cresyl glucuronide; p cresyl sulfate; SRM of LC ESI MS MS; Uremic solute generation, and mechanisms

Indexed keywords

EID: 84888695991     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118424032.ch5     Document Type: Chapter

References (61)

1. Meyer TW, Hostetter TH: Uremia. New Engl J Med 357:1316-1325, 2007.
2. Vanholder R, de Smet R: Pathophysiologic effects of uremic retention solutes. J Am Soc Nephrol 10:1815-1823, 1999.
3. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N: Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 20:1048-1056, 2005.
4. Vanholder R, Baurmeister U, Brunet P, Cohen G, Glorieux G, Jankowski J: A bench to bedside view of uremic toxins. J Am Soc Nephrol 19:863-870, 2008.
5. Vanholder R, de Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W: Review on uremic toxins: Classification, concentration, and interindividual variability. Kidney Int 63:1934-1943, 2003.
6. Vanholder R, Glorieux G, de Smet R, Lameire N: New insights in uremic toxins. Kidney Int 63:S6-S10, 2003.
7. Jourde-Chiche N, Dou L, Cerini C, Dignat-George F, Vanholder R, Brunet P: Proteinbound toxins-update 2009. Sem Dial 22:334-339, 2009.
8. Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temmar M, Choukroun G, Vanholder R, Massy ZA: Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 4:1551-1558, 2009.
9. Liabeuf S, Barreto DV, Barreto FC, Meert N, Glorieux G, Schepers E, Temmar M, Choukroun G, Vanholder R, Massy ZA: Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant 25:1183-1191, 2010.
10. Wang CP, Lu LF, Yu TH, Hung WC, Chiu CA, Chung FM, Yeh LR, Chen HJ, Lee YJ, Houng JY: Serum levels of total p-cresylsulphate are associated with angiographic coronary atherosclerosis severity in stable angina patients with early stage of renal failure. Atherosclerosis 211:579-583, 2010.
11. Lesaffer G, De SR, Lameire N, Dhondt A, Duym P, Vanholder R: Intradialytic removal of protein-bound uraemic toxins: Role of solute characteristics and of dialyser membrane. Nephrol Dial Transplant 15:50-57, 2000.
12. Meert N, Beerenhout C, Schepers E, Glorieux G, Kooman J, Vanholder R: Evolution of protein-bound uraemic solutes during predilution haemofiltration. J Nephrol 22:352-357, 2009.
13. Vanholder RC, Ringoir SM: Adequacy of dialysis-A critical analysis. Kidney Int 42:540-558, 1992.
14. Martin AK: The origin of urinary aromatic compounds excreted by ruminants. 3. The metabolism of phenolic compounds to simple phenols. Br J Nutr 48:497-507, 1982.
15. Vanholder R, de Smet R, Lesaffer G: p-Cresol: A toxin revealing many neglected but relevant aspects of uraemic toxicity. Nephrol Dial Transplant 14:2813-2815, 1999.
16. Hanioka H, Hamamura M, Kakino K, Ogata H, Jinno H, Takahashi A, Nishimura T, Ando M: Dog liver microsomal P450 enzyme-mediated toluene biotransformation. Xenobiotica 25:1207-1217, 1995.
17. Madyastha KM, Raj CP: Evidence for the formation of a known toxin, p-cresol, from menthofuran. Biochem Biophys Res Commun 177:440-446, 1991.
18. Hida M, Aiba Y, Sawamura S, Suzuki N, Satoh T, Koga Y: Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron 74:349-355, 1996.
19. Guarner F, Malagelada JR: Gut flora in health and disease. Lancet 361:512-519, 2003.
20. Yokoyama MT, Tabori C, Miller ER, Hogberg MG: The effects of antibiotics in the weanling pig diet on growth and the excretion of volatile phenolic and aromatic bacterial metabolites. Am J Clin Nutr 35:1417-1424, 1982.
21. Bammens B, Verbeke K, Vanrenterghem Y, Evenepoel P: Evidence for impaired assimilation of protein in chronic renal failure. Kidney Int 64:2196-2203, 2003.
22. Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y: Impairment of small intestinal protein assimilation in patients with end-stage renal disease: Extending the malnutrition-inflammation-atherosclerosis concept. Am J Clin Nutr 80:1536-1543, 2004.
23. Bone E, Tamm A, Hill M: Production of urinary phenols by gut bacteria and their possible role in causation of large bowel cancer. Am J Clin Nutr 29:1448-1454, 1976.
24. Cassidy MK, Houston JB: In vivo capacity of hepatic and extrahepatic enzymes to conjugate phenol. Drug Metabol Dispos 12:619-624, 1984.
25. Pedersen G, Brynskov J, Saermark T: Phenol toxicity and conjugation in human colonic epithelial cells. Scand J Gastroenterol 37:74-79, 2002.
26. Aronov PA, Luo FJG, Plummer NS, Quan Z, Holmes S, Hostetter TH, Meyer TW: Colonic contribution to uremic solutes. J Am Soc Nephrol 22:1769-1776, 2011.
27. Krieter DH, Hackl A, Rodriguez A, Chenine L, Moragues HL, Lemke HD, Wanner C, Canaud B: Protein-bound uraemic toxin removal in haemodialysis and post-dilution haemodiafiltration. Nephrol Dial Transplant 25:212-218, 2010.
28. Meert N, Eloot S, Waterloos MA, Van Landschoot M, Dhondt A, Glorieux G, Ledebo I, Vanholder R: Effective removal of protein-bound uraemic solutes by different convective strategies: A prospective trial. Nephrol Dial Transplant 24:562-570, 2009.
29. Meijers BKI, De Loor H, Bammens B, Verbeke K, Vanrenterghem Y, Evenepoel P: p-Cresyl sulfate and indoxyl sulfate in hemodialysis patients. Clin J Am Soc Nephrol 4:1932-1938, 2009.
30. Pham NM, Recht NS, Hostetter TH, Meyer TW: Removal of the protein-bound solutes indican and p-cresol sulfate by peritoneal dialysis. Clin J Am Soc Nephrol 3:85-90, 2008.
31. Kikuchi K, Itoh Y, Tateoka R, Ezawa A, Murakami K, Niwa T: Metabolomic analysis of uremic toxins by liquid chromatography/electrospray ionization-tandem mass spectrometry. J Chromatogr B 878:1662-1668, 2010.
32. Kikuchi K, Itoh Y, Tateoka R, Ezawa A, Murakami K, Niwa T: Metabolomic search for uremic toxins as indicators of the effect of an oral sorbent AST-120 by liquid chromatography/tandem mass spectrometry. J Chromatogr B 878:2997-3002, 2010.
33. Meert N, Schepers E, Glorieux G, Van Landschoot M, Goeman J, Waterloos MA, Dhondt A, Van der Eycken J, Vanholder R: Novel method for simultaneous determination of p-cresylsulphate and p-cresylglucuronide: Clinical data and pathophysiological implications. Nephrol Dial Transplant 2011, doi: 10.1093/ndt/gfr672.
34. Martinez AW, Recht NS, Hostetter TH, Meyer TW: Removal of p-cresol sulfate by hemodialysis. J Am Soc Nephrol 16:3430-3436, 2005.
35. De Loor H, Mejers BKI, Meyer TW, Bammens B, Verbeke K, Dehaen W, Evenepoel P: Sodium octanoate to reverse indoxyl sulfate and p-cresyl sulfate albumin binding in uremic and normal serum during sample preparation followed by fluorescence liquid chromatography. J Chromatogr A 1216:4684-4688, 2009.
36. de Loor H, Bammens B, Evenepoel P, De PV, Verbeke K: Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum. Clin Chem 51:1535-1538, 2005.
37. Eloot S, Schepers E, Barreto DV, Barreto FC, Liabeuf S, Van Biesen W, Verbeke F, Glorieux G, Choukroun G, Massy Z, Vanholder R: Estimated glomerular filtration rate is a poor predictor of concentration for a broad range of uremic toxins. Clin J Am Soc Nephrol 6:1266-1273, 2011.
38. Schepers E, Meert N, Glorieux G, Goeman J, Van der EJ, Vanholder R: p-Cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant 22:592-596, 2007.
39. Meijers BK, Van KS, Verbeke K, Dehaen W, Vanrenterghem Y, Hoylaerts MF, Evenepoel P: The uremic retention solute p-cresyl sulfate and markers of endothelial damage. Am J Kidney Dis 54:891-901, 2009.
40. Vanholder R, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Massy ZA, Rodriguez M, Stegmayr B, Stenvinkel P, Wratten ML: Uremic toxicity: Present state of the art. Int J Artif Organs 24:695-725, 2001.
41. Bammens B, Evenepoel P, Keuleers H, Verbeke K, Vanrenterghem Y: Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int 69:1081-1087, 2006.
42. Meijers BKI, Bammens B, De Moor B, Verbeke K, Vanrenterghem Y, Evenepoel P: Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int 73:1174-1180, 2008.
43. de Smet R, van Kaer J, van Vlem B, De Cubber A, Brunet P, Lameire N, Vanholder R: Toxicity of free p-cresol: A prospective and cross-sectional analysis. Clin Chem 49:470-478, 2003.
44. Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y: Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney Int 64:2238-2243, 2003.
45. Massy ZA, Barreto DV, Barreto FC, Vanholder R: Uraemic toxins for consideration by the cardiologist: Beyond traditional and non-traditional cardiovascular risk factors. Atherosclerosis 211:381-383, 2010.
46. Geypens B, Claus D, Evenepoel P, Hiele M, Maes B, Peeters M, Rutgeerts P, Ghoos Y: Influence of dietary protein supplements on the formation of bacterial metabolites in the colon. Gut 41:70-76, 1997.
47. Ling WH, Hanninen O: Shifting from a conventional diet to an uncooked vegan diet reversibly alters fecal hydrolytic activities in humans. J Nutr 122:924-930, 1992.
48. Birkett A, Muir J, Phillips J, Jones G, Odea K: Resistant starch lowers fecal concentrations of ammonia and phenols in humans. Am J Clin Nutr 63:766-772, 1996.
49. Bliss DZ, Stein TP, Schleifer CR, Settle RG: Supplementationwith gumarabic fiber increases fecal nitrogen excretion and lowers serum urea nitrogen concentration in chronic renal failure patients consuming a low-protein diet. Am J Clin Nutr 63:392-398, 1996.
50. De Preter V, Coopmans T, Rutgeerts P, Verbeke K: Influence of long-term administration of lactulose and Saccharomyces boulardii on the colonic generation of phenolic compounds in healthy human subjects. J Am Coll Nutr 25:541-549, 2006.
51. De Preter V, Vanhoutte T, Huys G, Swings J, De Vuyst L, Rutgeerts P, Verbeke K: Effects of Lactobacillus casei Shirota, Bifidobacterium breve, and oligofructose-enriched inulin on colonic nitrogen-protein metabolism in healthy humans. Am J Physiol Gastrointest Liver Physiol 292:G358-G368, 2007.
52. Ranganathan N, Patel BG, Ranganathan P, Marczely J, Dheer R, Pechenyak B, Dunn SR, Verstraete W, Decroos K, Mehta R, Friedman EA: In vitro and in vivo assessment of intraintestinal bacteriotherapy in chronic kidney disease. ASAIO J 52:70-79, 2006.
53. Taki K, Takayama F, Niwa T: Beneficial effects of bifidobacteria in a gastroresistant seamless capsule on hyperhomocysteinemia in hemodialysis patients. J Ren Nutr 15:77-80, 2005.
54. Niwa T, Ise M, Miyazaki T, Meada K: Suppressive effect of an oral sorbent on the accumulation of p-cresol in the serumof experimental uremic rats. Nephron 65:82-87, 1993.
55. Schulman G, Agarwal R, Acharya M, Berl T, Blumenthal S, Kopyt N: A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. Am J Kidney Dis 47:565-577, 2006.
56. Akizawa T, Asano Y, Morita S, Wakita T, Onishi Y, Fukuhara S, Gejyo F, Matsuo S, Yorioka N, Kurokawa K: Effect of a carbonaceous oral adsorbent on the progression of CKD: A multicenter, randomized, controlled trial. Am J Kidney Dis 54:459-467, 2009.
57. Ueda H, Shibahara N, Takagi S, Inoue T, Katsuoka Y: AST-120, an oral adsorbent, delays the initiation of dialysis in patients with chronic kidney diseases. Ther Apher Dial 11:189-195, 2007.
58. Ueda H, Shibahara N, Takagi S, Inoue T, Katsuoka Y: AST-120 treatment in pre-dialysis period affects the prognosis in patients on hemodialysis. Ren Fail 30:856-860, 2008.
59. Evenepoel P, Bammens B, Verbeke K, Vanrenterghem Y: Superior dialytic clearance of beta(2)-microglobulin and p-cresol by high-flux hemodialysis as compared to peritoneal dialysis. Kidney Int 70:794-799, 2006.
60. Vanholder R, Meert N, Van Biesen W, Meyer T, Hostetter T, Dhondt A, Eloot S: Why do patients on peritoneal dialysis have low blood levels of protein-bound solutes? Nat Clin Pract Nephrol 5:130-131, 2009.
61. Lameire N, Vanholder R, de Smet R: Uremic toxins and peritoneal dialysis. Kidney Int 59: S292-S297, 2001.